It's easier than you think to help find ways to cure, prevent and treat type 1 diabetes.

Researchers all over Australia are running clinical trials for type 1 diabetes. If you would like to participate or learn more about one of these trials, use our clinical trial finder below. 

These are the current clinical trials in your state. If none of these are suited to you at this point, sign up to become a T1D Game Changer, and we'll keep you updated as to when new trial opportunities arise. 

Researchers: Submit your clinical research project on our trial finder.

Australian Capital Territory | New South Wales | Northern Territory | Queensland | South Australia | Tasmania | Victoria | Western Australia

 Photo: The Salmon family of New South Wales. Max (age 6) was diagnosed with type 1 diabetes in 2010.

Trial Finder:

Australian Capital Territory

TrialNet studies to prevent type 1 diabetes

Family members of people with type 1 diabetes are at increased risk of developing the disease. This risk can be clarified using a blood test for antibodies, which are found in around 1 in 30 family members. Those with antibodies are offered opportunities to participate in trials of therapies to prevent them ever getting diabetes.

Inclusion criteria:

  • Individuals aged 1-45 with an immediate family member with T1D
  • Individuals aged 1-20 with an extended family member with T1D

Contact details: Felicity Healy and Leanne Redl at Melbourne Health: 03 9342 7063, felicity.healy@mh.org.au or leanne.redl@mh.org.au

Find out more.

The effect of work and family conflict on quality of life of parents and children

This study will investigate how work-family conflict affects quality of life for children living with a chronic illness like type 1 diabetes and their parents.  We are especially interested in how these challenges are faced, and if any differences exist between these parents and those of children without a chronic illness.

 

Inclusion criteria: Australian parents of a child aged 5-12 years, working at least 2 days per week. Parents of children with type 1 diabetes, asthma, eczema or no health conditions are eligible to participate.

Contact details:  Antonia Kish at the University of Queensland on 0733657171 or antonia.kish@uqconnect.edu.au

New South Wales

Nox 1/4 inhibition to treat kidney disease in type 1 diabetes

This study will test whether a new tablet can help to treat diabetic kidney disease. The study will last for 56 weeks, and participants will be allocated to receive either the new tablet or placebo. There will be 10 study visits. 

Inclusion criteria:  Adults (18-70years) with T1D, with HbA1c<10%, and with albumin (protein) in the urine

Contact details for NSW study sites:  a) Rachel McGrath at Royal North Shore Hospital on rachel.mcgrath@sydney.edu.au  b) Yi Shi at Royal Prince Alfred Hospital on yi.shi@health.nsw.gov.au or c) Claudia Bishop at Campbelltown Hospital on claudia.bishop@westernsydney.edu.au

The fenofibrate and microvascular events in type 1 diabetes (FAME 1) eye study

The FAME 1 Eye Study is investigating whether fenofibrate, a drug that is already on the market to lower cholesterol and blood fats, can slow or reverse eye damage and other complications in adults with T1D. We know that fenofibrate improves blood fats and slows the progression of eye damage in people with type 2 diabetes, this study will see if it has the same effect in type 1 diabetes. 

Inclusion criteria:  Adults with T1D and non-proliferative retinopathy

Contact details: The NHMRC Clinical Trials Centre on 1800 158 629 or fame1eye@ctc.usyd.edu.au

Find out more.

Environmental Determinants of Islet Autoimmunity (ENDIA)

The ENDIA (Environmental Determinants of Islet Autoimmunity) study is looking into what contributes to the development of Type 1 Diabetes in early childhood. Type 1 Diabetes in children is twice as common as it was 20 years ago. This is because our environment has changed and predisposed children are more likely to develop Type 1 Diabetes. If we can understand exactly what in the environment is harmful or protective, we can develop strategies to prevent Type 1 Diabetes.

Inclusion criteria:

  • Women who are pregnant with a baby that will have a first-degree relative with T1D
  • Newborn babies less than 6-months old with a first-degree relative with T1D

Contact details: 08 8161 8747 or endia@adelaide.edu.au 

Find out more.

Hypo-Unaware Closed-Loop studies 

Do you have type 1 diabetes? Managed with multiple daily injections? Have you lost the warning symptoms of a hypo? Have you had at least one severe hypo requiring the assistance of another person in the last year? Would you like to advance research into diabetes management and also have the opportunity to trial the 'artificial pancreas' or hybrid closed-loop insulin pump?  

Inclusion criteria:  Adults (25-70 years) with T1D that answered yes to all of the above questions 

Contact details: Marlene Payk at Westmead Hospital on 02 8890 6466 or WSLHD-Westmead-AdultHCLS@health.nsw.gov.au  

Investigation of a closed loop device for young people with type 1 diabetes 

A hybrid closed loop system  provides automated control of basal insulin delivery, offering the potential to reduce glucose variability outside of the healthy  range compared with standard treatment. This study will explore the use of a hybrid closed loop system (Medtronic Minimed 670G) vs. standard treatment (current pump or multiple daily injections with or without continuous glucose monitoring) on health outcomes and quality of life.

Inclusion criteria:  Aged 12-25 years with T1D (duration >1 year) treated with either multiple daily injections or an insulin pump and with HbA1c <10.5%

Contact details: Helen Daniels, Telethon Kid's Institute Perth on 08 64564622 or helen.daniels@health.wa.gov.au

ToGeTher: Type One Diabetes and Gut Therapy 

Recent research has shown that a specialised fibre supplement can prevent T1D in mice by influencing the gut microbiome (e.g. gut bacteria). This study is the first to trial this fibre supplement in adults already diagnosed with T1D to see whether there are any changes to your overall health, diabetes management and your gut microbiota. Participants will need to consume the fibre for 6 weeks and attend 5 appointments over 12 weeks. 

Inclusion criteria:  Adults (18-45 years) with T1D (>6 months duration) and stable management (not still producing your own insulin or not changed recently between injections and a pump), HbA1c <8.5%, no history or symptoms of gastrointestinal disease or malabsorption (e.g. coeliac disease), weight between 50-120kg, no antibotic usage currently or during the study.  

Contact details: Dr Kirstine Bell and Charles Perkins Centre, University of Sydney on 0400167043 or kirstine.bell@sydney.edu.au 

The Australasian Diabetes Data Network (ADDN)

ADDN connects real-time diabetes data about thousands of type 1 diabetes patients from specialist centres across on a single platform that allows for a long-term monitoring of diabetes outcomes and participation in clinical research.

Inclusion criteria: Children, adolescents and young adults with T1D

Contact details: info@addn.org.au 

Find out more.

TrialNet studies to prevent type 1 diabetes

Family members of people with type 1 diabetes are at increased risk of developing the disease. This risk can be clarified using a blood test for antibodies, which are found in around 1 in 30 family members. Those with antibodies are offered opportunities to participate in trials of therapies to prevent them ever getting diabetes.

Inclusion criteria:

  • Individuals aged 1-45 with an immediate family member with T1D
  • Individuals aged 1-20 with an extended family member with T1D

Contact details: Felicity Healy and Leanne Redl at Melbourne Health: 03 9342 7063, felicity.healy@mh.org.au or leanne.redl@mh.org.au

Find out more.

How does the type of dietary protein influence postprandial glycaemia in type 1 diabetes?

The iBolus:Protein Study will research the impact of the type of dietary protein on postprandial (after meal) blood glucose levels in adults with type 1 diabetes using an insulin pump. The study will compare 5 different types of protein (egg, beef, chicken, salmon and whey protein isolate) each served with 45g of carbohydrate (rice). The study involves 5 sessions, for 5.5 hours per session, total commitment 27.5 hours. 

Inclusion criteria: Aged 18-70 years with type 1 diabetes (>1 year duration), insulin pump therapy for greater than or equal to 3 months, HbA1c less than or equal to 8.5%, reliably performing self-monitoring of blood glucose levels at least four times daily/or using continuous glucose monitoring, fluency in English.

Contact details: Dr Kirstine Bell at USyd Charles Perkins Centre on 0400167043, or kirstine.bell@sydney.edu.au 

Find out more

Cord Reinfusion in Diabetes (CORD) Pilot Study

Cell Care is partnering with The Children’s Hospital at Westmead, NSW, in a world–first trial investigating the potential of cord blood to prevent or delay the onset of type 1 diabetes (T1D) in high risk children.

Find out more by contacting Phuong Phan
Email: cord.schn@health.nsw.gov.au
Telephone: 02 9845 1233

The Clinical Utility of Glycated Albumin as an Index of Glycaemic Control in Type 1 Diabetic Pregnancy and its ability to predict Neonatal Outcome

High birth weight is a common and important complication of type 1 diabetes in pregnancy, with adverse consequences for both mother and baby. Accurate determination of glycaemic control remains difficult due to limitations of current testing methods and parameters.  

This study is investigating the use of glycated albumin for monitoring glycaemic control in pregnancy, a test which has the potential to be more accurate, widely accessible and cost effective.

Inclusion criteria: Females aged over 18 with type 1 diabetes, pregnant and at 11-18 weeks gestation.

Contact details: Dr Rachel McGrath at Royal North Shore Hospital on 02 9463 1470, or rachel.mcgrath@health.nsw.gov.au

Find out more

HIIT T1D 

The ‘HIIT T1D’ study aims to see how a 12-week exercise program involving high-intensity interval training can improve health in people with type 1 diabetes. The exercise research study will look at the effects of the exercise program on glucose control (HbA1c), blood pressure,cholesterol, bodyweight and body composition, fitness, heart and liver health (MRI scans). Participants will undertake an individualised exercise program, and guidance to manage glucose for exercise.

Inclusion criteria: Age 18-70 years, T1D duration >1 year, HbA1c 7.5-10.5%, Body mass index (BMI) 25 or greater and currently exercising less than 150 minutes per week. 

Contact details: Dr Angela Lee, Royal Prince Alfred Hospital on 0422875160 or alee8473@uni.sydney.edu.au

The effect of work and family conflict on quality of life of parents and children 

This study will investigate how work-family conflict affects quality of life for children living with a chronic illness like type 1 diabetes and their parents.  We are especially interested in how these challenges are faced, and if any differences exist between these parents and those of children without a chronic illness.

Inclusion criteria: Australian parents of a child aged 5-12 years, working at least 2 days per week. Parents of children with type 1 diabetes, asthma, eczema or no health conditions are eligible to participate.

Contact details:  Antonia Kish at the University of Queensland on 0733657171 or antonia.kish@uqconnect.edu.au

Is dysfunction of brain blood vessels associated with cognitive impairment in type 1 diabetes? (INeuroT1D)

The study group's goal is to estimate the contributions of age and diabetes-specific brain changes observed in older age T1D. Namely, they aim to evaluate cerebral blood vessel function and blood flow as well as hearing control and their relationships with how well the brain performs during mental tasks, and if type 1 diabetes can impact this performance in later life, when compared to non-diabetic participants.

Inclusion criteria: Age 30-80 years, T1D diagnosed before 18 years, No advanced T1D complications such as blindness or deafness, Not hospitalised for severe glycemic events in the last 3 months, No liver or kidney disease, No malignant cancer, Not pregnant, No neurological conditions including stroke, TIA, major depression, multiple sclerosis, parkinson's disease, dementia or mild cognitive impairement. 

Contact details: Dr Rachel Wong, University of Newcastle NSW on 0249216408 or rachel.wong@newcastle.edu.au

Northern Territory

TrialNet studies to prevent type 1 diabetes

Family members of people with type 1 diabetes are at increased risk of developing the disease. This risk can be clarified using a blood test for antibodies, which are found in around 1 in 30 family members. Those with antibodies are offered opportunities to participate in trials of therapies to prevent them ever getting diabetes.

Inclusion criteria:

  • Individuals aged 1-45 with an immediate family member with T1D
  • Individuals aged 1-20 with an extended family member with T1D

Contact details: Felicity Healy and Leanne Redl at Melbourne Health: 03 9342 7063, felicity.healy@mh.org.au or leanne.redl@mh.org.au

Find out more.

The effect of work and family conflict on quality of life of parents and children 

This study will investigate how work-family conflict affects quality of life for children living with a chronic illness like type 1 diabetes and their parents.  We are especially interested in how these challenges are faced, and if any differences exist between these parents and those of children without a chronic illness.

Inclusion criteria: Australian parents of a child aged 5-12 years, working at least 2 days per week. Parents of children with type 1 diabetes, asthma, eczema or no health conditions are eligible to participate.

Contact details:  Antonia Kish at the University of Queensland on 0733657171 or antonia.kish@uqconnect.edu.au

Queensland

Nox 1/4 inhibition to treat kidney disease in type 1 diabetes

This study will test whether a new tablet can help to treat diabetic kidney disease. The study will last for 56 weeks, and participants will be allocated to receive either the new tablet or placebo. There will be 10 study visits. 

Inclusion criteria:  Adults (18-70years) with T1D, with HbA1c<10%, and with albumin (protein) in the urine

Contact details for QLD study site: Erika Vardanega at Royal Brisbane and Women's Hospital on erika.vardanega@health.qld.gov.au

The Australasian Diabetes Data Network (ADDN)

The ADDN project will build a national picture of young type 1 diabetes patients by capturing de-identified patient population data from newly diagnosed children and children with established type 1 diabetes. ADDN connects diabetes data from specialist centres across Australia and New Zealand on a single platform. This study is administered by the Australasian Paediatric Endocrine Group (APEG), which is an organisation representing health professionals caring for children with diabetes.

Contact details: info@addn.org.au 

Find out more.

TrialNet studies to prevent type 1 diabetes

Family members of people with type 1 diabetes are at increased risk of developing the disease. This risk can be clarified using a blood test for antibodies, which are found in around 1 in 30 family members. Those with antibodies are offered opportunities to participate in trials of therapies to prevent them ever getting diabetes.

Inclusion criteria:

  • Individuals aged 1-45 with an immediate family member with T1D
  • Individuals aged 1-20 with an extended family member with T1D

Contact details: Felicity Healy and Leanne Redl at Melbourne Health: 03 9342 7063, felicity.healy@mh.org.au or leanne.redl@mh.org.au

Find out more.

Environmental Determinants of Islet Autoimmunity (ENDIA)

The ENDIA (Environmental Determinants of Islet Autoimmunity) study is looking into what contributes to the development of Type 1 Diabetes in early childhood. Type 1 Diabetes in children is twice as common as it was 20 years ago. This is because our environment has changed and predisposed children are more likely to develop Type 1 Diabetes. If we can understand exactly what in the environment is harmful or protective, we can develop strategies to prevent Type 1 Diabetes.

Inclusion criteria:

  • Women who are pregnant with a baby that will have a first-degree relative with T1D
  • Newborn babies less than 6-months old with a first-degree relative with T1D

Contact details: 08 8161 8747 or endia@adelaide.edu.au 

Find out more.

Identification of children with type 1 diabetes suitable for antigen-specific tolerising immunotherapy: T-cell response to pro-insulin

The study group have shown that targeting specific auto-antigens (body proteins that appear foreign to the immune system) can successfully control autoimmune responses in animal studies of T1D and other human autoimmune disease. 

This study tests whether this approach can switch the immune response from a destructive to a protective response towards beta cells in human T1D. They require blood samples from children/young adults with T1D and will test the immune responses to antigen-specific medications. 

Inclusion criteria: Children and young adults with type 1 diabetes, diagnosed within the last 12 months. 

Contact details: Yassmin Musthaffa at the University of Qld on y.musthaffa@uq.edu.au

Efficacy of the Positive Parenting Program (Triple P) for parents of young children with type 1 diabetes

Type 1 diabetes is associated with higher rates of behavioural and emotional problems, which can persist into adulthood. Parents of children with diabetes are often unsure about what is appropriate for their child, and struggle with incorporating tasks into their day-to-day routines.

This study aims to evaluate the efficacy of a brief, group-based parenting intervention for parents of children with type 1 diabetes, and its potential to lead to improved child behavioural and emotional adjustment, better family wellbeing, and healthier children.

Inclusion criteria: Families with a 2 - 10 year old child with type 1 diabetes

Contact details: Aditi Lohan at the University of Qld on 07 3365 7689 or aditi.lohan@uqconnect.edu.au

Find out more.

The effect of work and family conflict on quality of life of parents and children 

This study will investigate how work-family conflict affects quality of life for children living with a chronic illness like type 1 diabetes and their parents.  We are especially interested in how these challenges are faced, and if any differences exist between these parents and those of children without a chronic illness.

Inclusion criteria: Australian parents of a child aged 5-12 years, working at least 2 days per week. Parents of children with type 1 diabetes, asthma, eczema or no health conditions are eligible to participate.

Contact details:  Antonia Kish at the University of Queensland on 0733657171 or antonia.kish@uqconnect.edu.au

South Australia

Nox 1/4 inhibition to treat kidney disease in type 1 diabetes

This study will test whether a new tablet can help to treat diabetic kidney disease. The study will last for 56 weeks, and participants will be allocated to receive either the new tablet or placebo. There will be 10 study visits. 

Inclusion criteria:  Adults (18-70years) with T1D, with HbA1c<10%, and with albumin (protein) in the urine

Contact details for SA study site:  Denise Healy at Royal Adelaide Hospital on denise.healy@sahmri.com

Investigation of a closed loop device for young people with type 1 diabetes 

A hybrid closed loop system  provides automated control of basal insulin delivery, offering the potential to reduce glucose variability outside of the healthy  range compared with standard treatment. This study will explore the use of a hybrid closed loop system (Medtronic Minimed 670G) vs. standard treatment (current pump or multiple daily injections with or without continuous glucose monitoring) on health outcomes and quality of life.

Inclusion criteria:  Aged 12-25 years with T1D (duration >1 year) treated with either multiple daily injections or an insulin pump and with HbA1c <10.5%

Contact details: Helen Daniels, Telethon Kid's Institute Perth on 08 64564622 or helen.daniels@health.wa.gov.au

The fenofibrate and microvascular events in type 1 diabetes (FAME 1) eye study

The FAME 1 Eye Study is investigating whether fenofibrate, a drug that is already on the market to lower cholesterol and blood fats, can slow or reverse eye damage and other complications in adults with T1D. We know that fenofibrate improves blood fats and slows the progression of eye damage in people with type 2 diabetes, this study will see if it has the same effect in type 1 diabetes. 

Adults with T1D and non-proliferative retinopathy

Contact details: The NHMRC Clinical Trials Centre on 1800 158 629 or fame1eye@ctc.usyd.edu.au

Find out more.

The Australasian Diabetes Data Network (ADDN)

The ADDN project will build a national picture of young type 1 diabetes patients by capturing de-identified patient population data from newly diagnosed children and children with established type 1 diabetes. ADDN connects diabetes data from specialist centres across Australia and New Zealand on a single platform. This study is administered by the Australasian Paediatric Endocrine Group (APEG), which is an organisation representing health professionals caring for children with diabetes.

Contact details: info@addn.org.au 

Find out more.

TrialNet studies to prevent type 1 diabetes

Family members of people with type 1 diabetes are at increased risk of developing the disease. This risk can be clarified using a blood test for antibodies, which are found in around 1 in 30 family members. Those with antibodies are offered opportunities to participate in trials of therapies to prevent them ever getting diabetes.

Inclusion criteria:

  • Individuals aged 1-45 with an immediate family member with T1D
  • Individuals aged 1-20 with an extended family member with T1D

Contact details: Felicity Healy and Leanne Redl at Melbourne Health: 03 9342 7063, felicity.healy@mh.org.au or leanne.redl@mh.org.au

Find out more.

Environmental Determinants of Islet Autoimmunity (ENDIA)

The ENDIA (Environmental Determinants of Islet Autoimmunity) study is looking into what contributes to the development of Type 1 Diabetes in early childhood. Type 1 Diabetes in children is twice as common as it was 20 years ago. This is because our environment has changed and predisposed children are more likely to develop Type 1 Diabetes. If we can understand exactly what in the environment is harmful or protective, we can develop strategies to prevent Type 1 Diabetes.

Inclusion criteria:

  • Women who are pregnant with a baby that will have a first-degree relative with T1D
  • Newborn babies less than 6-months old with a first-degree relative with T1D

Contact details: 08 8161 8747 or endia@adelaide.edu.au 

Find out more.

The effect of work and family conflict on quality of life of parents and children 

This study will investigate how work-family conflict affects quality of life for children living with a chronic illness like type 1 diabetes and their parents.  We are especially interested in how these challenges are faced, and if any differences exist between these parents and those of children without a chronic illness.

Inclusion criteria: Australian parents of a child aged 5-12 years, working at least 2 days per week. Parents of children with type 1 diabetes, asthma, eczema or no health conditions are eligible to participate.

Contact details:  Antonia Kish at the University of Queensland on 0733657171 or antonia.kish@uqconnect.edu.au

 

Tasmania

TrialNet studies to prevent type 1 diabetes

Family members of people with type 1 diabetes are at increased risk of developing the disease. This risk can be clarified using a blood test for antibodies, which are found in around 1 in 30 family members. Those with antibodies are offered opportunities to participate in trials of therapies to prevent them ever getting diabetes.

Inclusion criteria:

  • Individuals aged 1-45 with an immediate family member with T1D
  • Individuals aged 1-20 with an extended family member with T1D

Contact details: Felicity Healy and Leanne Redl at Melbourne Health: 03 9342 7063, felicity.healy@mh.org.au or leanne.redl@mh.org.au

Find out more.

The effect of work and family conflict on quality of life of parents and children

This study will investigate how work-family conflict affects quality of life for children living with a chronic illness like type 1 diabetes and their parents.  We are especially interested in how these challenges are faced, and if any differences exist between these parents and those of children without a chronic illness.

Inclusion criteria: Australian parents of a child aged 5-12 years, working at least 2 days per week. Parents of children with type 1 diabetes, asthma, eczema or no health conditions are eligible to participate.

Contact details:  Antonia Kish at the University of Queensland on 0733657171 or antonia.kish@uqconnect.edu.au

Victoria

Nox 1/4 inhibition to treat kidney disease in type 1 diabetes

This study will test whether a new tablet can help to treat diabetic kidney disease. The study will last for 56 weeks, and participants will be allocated to receive either the new tablet or placebo. There will be 10 study visits. 

Inclusion criteria:  Adults (18-70years) with T1D, with HbA1c<10%, and with albumin (protein) in the urine

Contact details:  Maria Lawton at Baker Heart and Diabetes Institute (lead site) on 03 8532 1835 or maria.lawton@baker.edu.au

Investigation of a closed loop device for young people with type 1 diabetes 

A hybrid closed loop system  provides automated control of basal insulin delivery, offering the potential to reduce glucose variability outside of the healthy  range compared with standard treatment. This study will explore the use of a hybrid closed loop system (Medtronic Minimed 670G) vs. standard treatment (current pump or multiple daily injections with or without continuous glucose monitoring) on health outcomes and quality of life.

Inclusion criteria:  Aged 12-25 years with T1D (duration >1 year) treated with either multiple daily injections or an insulin pump and with HbA1c <10.5%

Contact details: Helen Daniels, Telethon Kid's Institute Perth on 08 64564622 or helen.daniels@health.wa.gov.au

The fenofibrate and microvascular events in type 1 diabetes (FAME 1) eye study

The FAME 1 Eye Study is investigating whether fenofibrate, a drug that is already on the market to lower cholesterol and blood fats, can slow or reverse eye damage and other complications in adults with T1D. We know that fenofibrate improves blood fats and slows the progression of eye damage in people with type 2 diabetes, this study will see if it has the same effect in type 1 diabetes. 

Adults with T1D and non-proliferative retinopathy

Contact details: The NHMRC Clinical Trials Centre on 1800 158 629 or fame1eye@ctc.usyd.edu.au

Find out more.

The Australasian Diabetes Data Network (ADDN)

The ADDN project will build a national picture of young type 1 diabetes patients by capturing de-identified patient population data from newly diagnosed children and children with established type 1 diabetes. ADDN connects diabetes data from specialist centres across Australia and New Zealand on a single platform. This study is administered by the Australasian Paediatric Endocrine Group (APEG), which is an organisation representing health professionals caring for children with diabetes.

Contact details: info@addn.org.au 

Find out more.

TrialNet studies to prevent type 1 diabetes

Family members of people with type 1 diabetes are at increased risk of developing the disease. This risk can be clarified using a blood test for antibodies, which are found in around 1 in 30 family members. Those with antibodies are offered opportunities to participate in trials of therapies to prevent them ever getting diabetes.

Inclusion criteria:

  • Individuals aged 1-45 with an immediate family member with T1D
  • Individuals aged 1-20 with an extended family member with T1D

Contact details: Felicity Healy and Leanne Redl at Melbourne Health: 03 9342 7063, felicity.healy@mh.org.au or leanne.redl@mh.org.au

Find out more.

Environmental Determinants of Islet Autoimmunity (ENDIA)

The ENDIA (Environmental Determinants of Islet Autoimmunity) study is looking into what contributes to the development of Type 1 Diabetes in early childhood. Type 1 Diabetes in children is twice as common as it was 20 years ago. This is because our environment has changed and predisposed children are more likely to develop Type 1 Diabetes. If we can understand exactly what in the environment is harmful or protective, we can develop strategies to prevent Type 1 Diabetes.

Inclusion criteria:

  • Women who are pregnant with a baby that will have a first-degree relative with T1D
  • Newborn babies less than 6-months old with a first-degree relative with T1D

Contact details: 08 8161 8747 or endia@adelaide.edu.au 

Find out more.

Comparison of renal function in pregnant women with and without diabetes

Find out more by emailing: jmseah@gmail.com
Telephone: 0412 931 059

Empagliflozin to reduce insulin use in recently diagnosed diabetes

Empagliflozin has been used for over a decade to treat type 2 diabetes and, more recently, has been shown to lower insulin requirements in people with long-standing type 1 diabetes. This trial will test whether empagliflozin helps reduce insulin requirements and preserves pancreas function in people with newly diagnosed diabetes. It is taken as a table once a day with food. The trial is sponsored by Melbourne Health and is based at the Royal Melbourne Hospital.

Inclusion criteria:

  • Recent diagnosis of type 1 diabetes (within 100 days)
  • Age 18 to 40

Contact details: Dr John Wentworth at Royal Melbourne Hospital on 03 9342 7063 or wentworth@wehi.edu.au

Find out more.

The effect of work and family conflict on quality of life of parents and children 

This study will investigate how work-family conflict affects quality of life for children living with a chronic illness like type 1 diabetes and their parents.  We are especially interested in how these challenges are faced, and if any differences exist between these parents and those of children without a chronic illness.

Inclusion criteria: Australian parents of a child aged 5-12 years, working at least 2 days per week. Parents of children with type 1 diabetes, asthma, eczema or no health conditions are eligible to participate.

Contact details:  Antonia Kish at the University of Queensland on 0733657171 or antonia.kish@uqconnect.edu.au 

 

Western Australia

Nox 1/4 inhibition to treat kidney disease in type 1 diabetes

This study will test whether a new tablet can help to treat diabetic kidney disease. The study will last for 56 weeks, and participants will be allocated to receive either the new tablet or placebo. There will be 10 study visits. 

Inclusion criteria:  Adults (18-70years) with T1D, with HbA1c<10%, and with albumin (protein) in the urine

Contact details for WA site:  Michelle England at Fremantle Hospital on michelle.england@uwa.edu.au

Investigation of a closed loop device for young people with type 1 diabetes 

A hybrid closed loop system  provides automated control of basal insulin delivery, offering the potential to reduce glucose variability outside of the healthy  range compared with standard treatment. This study will explore the use of a hybrid closed loop system (Medtronic Minimed 670G) vs. standard treatment (current pump or multiple daily injections with or without continuous glucose monitoring) on health outcomes and quality of life.

Inclusion criteria:  Aged 12-25 years with T1D (duration >1 year) treated with either multiple daily injections or an insulin pump and with HbA1c <10.5%

Contact details: Helen Daniels, Telethon Kid's Institute Perth on 08 64564622 or helen.daniels@health.wa.gov.au

The fenofibrate and microvascular events in type 1 diabetes (FAME 1) eye study

The FAME 1 Eye Study is investigating whether fenofibrate, a drug that is already on the market to lower cholesterol and blood fats, can slow or reverse eye damage and other complications in adults with T1D. We know that fenofibrate improves blood fats and slows the progression of eye damage in people with type 2 diabetes, this study will see if it has the same effect in type 1 diabetes. 

Adults with T1D and non-proliferative retinopathy

Contact details: The NHMRC Clinical Trials Centre on 1800 158 629 or fame1eye@ctc.usyd.edu.au

Find out more.

The Australasian Diabetes Data Network (ADDN)

The ADDN project will build a national picture of young type 1 diabetes patients by capturing de-identified patient population data from newly diagnosed children and children with established type 1 diabetes. ADDN connects diabetes data from specialist centres across Australia and New Zealand on a single platform. This study is administered by the Australasian Paediatric Endocrine Group (APEG), which is an organisation representing health professionals caring for children with diabetes.

Contact details: info@addn.org.au 

Find out more.

TrialNet studies to prevent type 1 diabetes

Family members of people with type 1 diabetes are at increased risk of developing the disease. This risk can be clarified using a blood test for antibodies, which are found in around 1 in 30 family members. Those with antibodies are offered opportunities to participate in trials of therapies to prevent them ever getting diabetes.

Inclusion criteria:

  • Individuals aged 1-45 with an immediate family member with T1D
  • Individuals aged 1-20 with an extended family member with T1D

Contact details: Felicity Healy and Leanne Redl at Melbourne Health: 03 9342 7063, felicity.healy@mh.org.au or leanne.redl@mh.org.au

Find out more.

Environmental Determinants of Islet Autoimmunity (ENDIA)

The ENDIA (Environmental Determinants of Islet Autoimmunity) study is looking into what contributes to the development of Type 1 Diabetes in early childhood. Type 1 Diabetes in children is twice as common as it was 20 years ago. This is because our environment has changed and predisposed children are more likely to develop Type 1 Diabetes. If we can understand exactly what in the environment is harmful or protective, we can develop strategies to prevent Type 1 Diabetes.

Inclusion criteria:

  • Women who are pregnant with a baby that will have a first-degree relative with T1D
  • Newborn babies less than 6-months old with a first-degree relative with T1D

Contact details: 08 8161 8747 or endia@adelaide.edu.au 

Find out more.

The effect of work and family conflict on quality of life of parents and children 

This study will investigate how work-family conflict affects quality of life for children living with a chronic illness like type 1 diabetes and their parents.  We are especially interested in how these challenges are faced, and if any differences exist between these parents and those of children without a chronic illness.

Inclusion criteria: Australian parents of a child aged 5-12 years, working at least 2 days per week. Parents of children with type 1 diabetes, asthma, eczema or no health conditions are eligible to participate.

Contact details:  Antonia Kish at the University of Queensland on 0733657171 or antonia.kish@uqconnect.edu.au

Acute Hyperglycaemia in Type 1 Diabetes?   

Is short exposure to high blood glucose bad for you? Maybe not, according to The University of Western Australia. Researchers have found that a short rise in blood glucose does not increase levels of free radicals and now aim to understand these findings. They are looking for people with type 1diabetes aged 18-35 to take part in their study.

Inclusion criteria: Aged 18 - 35 years old.

Contact details:  Beth Fisher (0430027 399) Kate Sherwood (0474 635 528 or 21498924@student.uwa.edu.au) or Professor PaulFournier (08 6488 1356 or paul.fournier@uwa.edu.au)